Concepedia

Han Koo

HK

Statistics

Publications

9

Citations

557

H-Index

9

Active since

1996

Affiliations

Korea Research Institute of Bioscience and Biotechnology(Current)

Korea University of Science and Technology

University of Ulsan

Asan Medical Center

Ulsan College

Han Koo is an author at Korea Research Institute of Bioscience and Biotechnology specializing in oncology, molecular oncology, and medicine.

ORCID

Publications per year

1996–2023

9

Publications

9

Mitogen-activated protein kinase pathway-dependent tumor-specific survival signaling in melanoma cells through inactivation of the proapoptotic protein bad.

Kathryn M. Eisenmann, Matthew W. VanBrocklin, Nancy A. Staffend et al. · PubMed · 2003 · 146 citations

, , +17

Suppression of ras-mediated transformation and inhibition of tumor growth and angiogenesis by anthrax lethal factor, a proteolytic inhibitor of multiple MEK pathways

Nicholas S. Duesbery, James H. Resau, Craig P. Webb et al. · Proceedings of the National Academy of Sciences · 2001 · 104 citations · Full text

, , +13

Enhanced sensitivity to 1-beta-D-arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogenes.

Han Koo, Anne Monks, Andrei M. Mikheev et al. · PubMed · 1996 · 79 citations

, , +15

Pyruvate kinase isoenzyme M2 is a therapeutic target of gemcitabine-resistant pancreatic cancer cells

Dong Joon Kim, Young Soo Park, Mingu Kang et al. · Experimental Cell Research · 2015 · 78 citations

, , +14

AKT-induced PKM2 phosphorylation signals for IGF-1-stimulated cancer cell growth

Young Soo Park, Dong Joon Kim, Han Koo et al. · Oncotarget · 2016 · 52 citations · Full text

, , +17

1–5 of 9